Pfizer reaffirmed its full-year 2025 adjusted diluted EPS guidance and revised the revenue guidance to approximately $62.0 billion.
For full-year 2026, Pfizer provided revenue guidance ranging from $59.5 to $62.5 billion.
The company expects operational revenue growth of approximately 4% year-over-year in 2026 excluding COVID-19 and loss of exclusivity products.
Full-Year 2025 Guidance Reaffirmed
Pfizer reaffirmed its full-year 2025 adjusted diluted EPS guidance.
Revenue Guidance Revision
The full-year 2025 revenue guidance was revised to around $62.0 billion.
Full-Year 2026 Guidance
Pfizer provided full-year 2026 revenue guidance and adjusted diluted EPS expectations.
- Pfizer's strategic investments in pipeline and acquired assets in 2026 aim to fuel long-term growth.
- The company anticipates revenue impact from COVID-19 products and loss of exclusivity products in 2026.
- By focusing on key therapeutic areas and prioritizing development programs, Pfizer aims to optimize SI&A and R&D expenses for 2026.
Pfizer's financial guidance highlights its commitment to sustainable growth and value creation for shareholders in 2026.